TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3631319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ascorbic acid and haloperidol
Study: 31858658
Drug: Topical cosmetic
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cosmetic product combination (CCP)
Study: 22157201
Drug: sequential TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential TACE and RF ablation (n=69)
Study: 19539818
Drug: Group plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group plus individual therapy
Study: 19539818
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy only
Study: 15531038
Drug: Intradermal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal immunization with recombinant hepatitis B vaccine (3 doses)
Study: 15531038
Drug: Intramuscular immunization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular immunization with recombinant hepatitis B vaccine (3 doses)
Study: 20925201
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 6 mg/kg body weight
Study: 2979250
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg omeprazole
Study: 29318751
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg) plus best supportive care (BSC)
Study: 25600905
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation + aerobic training
Study: 14522788
Drug: Nonpegged hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpegged hydroxyapatite porous implants
Study: 14522788
Drug: Spherical alloplastic
Normalized name: ALLERGENIC EXTRACT, NIGROSPORA SPHAERICA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spherical alloplastic nonporous implants
Study: 14522788
Drug: Pegged hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegged hydroxyapatite implants
Study: 14522788
Drug: Sclera-covered hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclera-covered hydroxyapatite implants
Study: 14522788
Drug: Unwrapped porous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unwrapped porous polyethylene implants
Study: 11194951
Drug: Cis-platin-based chemotherapy
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-platin-based chemotherapy and irradiation
Study: 11194951
Drug: Epirubicin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-based chemotherapy and irradiation
Study: 8874988
Drug: Creatine phosphate
Normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine phosphate (CP) acute treatment (6 g CP intravenously)
Study: 8874988
Drug: Creatine phosphate
Normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine phosphate (CP) short-term treatment (6 g CP daily for 4 days)
Study: 1303072
Drug: Gluconolactone 14%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluconolactone 14% in solution (Nuvoderm lotion)
Study: 3889396
Drug: Seven days
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven days of ceftriaxone therapy
Study: 3889396
Drug: Ten days
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten days of ceftriaxone therapy
Study: 31337003
Drug: 0.6% povidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% povidone iodine eye drops (three day-prophylactic treatment before the injection)
Study: 31337003
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three day-prophylactic treatment)
Study: 29145589
Drug: 5-min treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-min treatment video (The ABCDs of Needle Pain Management)
Study: 23036277
Drug: Immediate radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate radiotherapy (either 50 Gy in 25 daily fractions or 40 Gy in 15 daily fractions)
Study: 23036277
Drug: No radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiotherapy (delayed salvage treatment)
Study: 19924121
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg nilotinib twice daily
Study: 19924121
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg nilotinib once daily
Study: 19924121
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg nilotinib once daily
Study: 16082604
Drug: Once-daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily subcutaneous enoxaparin (1.5 mg/kg)
Study: 16082604
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU bolus and 1250 IU/hour intravenous infusion)
Study: 8556964
Drug: Methadone dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone dose increases
Study: 2122711
Drug: High carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High carnitine supplementation (48 mg carnitine.kg‐1.d‐1)
Study: 722814
Drug: The opposite
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The opposite treatment sequence (sexual enhancement format for 3 weeks followed by fair-fight training for 3 additional weeks)
Study: 2439826
Drug: bopindolol 1-2
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 1-2 mg
Study: 2439826
Drug: metoprolol 100-200
Normalized name: metoprolol tartrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100-200 mg
Study: 2439826
Drug: bopindolol 1
Normalized name: bopindolol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 1 mg daily
Study: 2439826
Drug: bopindolol 8
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 8 mg once weekly
Study: 24842589
Drug: Web‐based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web‐based family problem‐solving treatment
Study: 18996761
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU of VitD weekly after RYGB
Study: 10700684
Drug: Intramuscularly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly administered dexamethasone acetate (IM Dex) approximately 1.7 mg/kg
Study: 10700684
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (PO Pred) approximately 2 mg/kg/d for 5 days
Study: 10700684
Drug: Intramuscularly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly administered dexamethasone acetate (IM Dex)
Study: 10700684
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (PO Pred)
Study: 9085957
Drug: Epinephrine test
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine test dose (15 microg) administered prior to spinal anesthesia
Study: 9085957
Drug: Epinephrine test
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine test dose (15 microg) administered 30 min after injection of spinal anesthesia
Study: 9085957
Drug: Epinephrine test
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine test dose (15 microg) administered at regression of sensory block to T-10
Study: 7682388
Drug: Adjuvant M-VAC
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant M-VAC chemotherapy
Study: 7682388
Drug: Palliative M-VAC
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative M-VAC chemotherapy
Study: 27806212
Drug: Behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatments for ADHD
Study: 26905792
Drug: Antibiotic information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic information application (app)
Study: 25633158
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 1% (DSG 1%)
Study: 18834373
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*1/*1 group
Study: 18834373
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*1/*10 group
Study: 18834373
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*10/*10 group
Study: 12618639
Drug: Integrated Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Care model (primary health care provided along with substance abuse treatment)
Study: 12618639
Drug: Independent Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent Care model (medical care provided independently from substance abuse treatment)
Study: 9973095
Drug: Maximal androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal androgen blockade (MAB) treatment arm
Study: 7701173
Drug: Running therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running therapy (twice a week for three months)
Study: 6793418
Drug: Ro 8‐8427
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 8‐8427 (Phenoro) at a daily dose of 100 mg
Study: 25831603
Drug: Fluoride group
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride group (non-sucrose food supplement containing fluoride, 1,500 μg/l per dose)
Study: 25831603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-sucrose food supplement without fluoride)
Study: 17666600
Drug: IV ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ferric carboxymaltose (less than or equal to 1,000 mg over 15 minutes, repeated weekly to achieve a total calculated replacement dose)
Study: 17666600
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulfate 325 mg orally thrice daily for 6 weeks)
Study: 16110231
Drug: Oral amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amino acids (12 g/day)
Study: 12177099
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg once-monthly intramuscular injection
Study: 12177099
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg oral dose
Study: 7986410
Drug: Progressors (men
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressors (men with HIV seroconversion prior to 1983 but with AIDS or CD4+ counts < 200 x 10(6)/l)
Study: 25733000
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg pegfilgrastim
Study: 25733000
Drug: 3.6 mg
Normalized name: menthol 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg pegfilgrastim
Study: 21534714
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) treatment followed by NeuroMuscular Retraining Therapy (NMRT)
Study: 19331489
Drug: Topiramate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (200 or 300 mg)
Study: 11246614
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU IFN daily for 2 months followed by 5 MU t.i.w. for a further 10 months (Group 7)
Study: 8039154
Drug: Pulsed high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed high dose chemotherapy
Study: 8039154
Drug: Dose intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose intensity regimens
Study: 2553568
Drug: PK 11195
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 11195 (10 mg IV)
Study: 2553568
Drug: PK 11195
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 11195 (100 mg oral)
Study: 2553568
Drug: PK 11195
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 11195 (200 mg oral)
Study: 2553568
Drug: PK 11195
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 11195 (400 mg oral)
Study: 59855
Drug: Ethamsylate treatment
Normalized name: ethamsylate
DrugBank: Etamsylate (DB13483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethamsylate treatment (Dicynene)
Study: 24800582
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/d and Furosemide 40 mg/d, adjusted every four days to a maximum of 400 mg/d and 160 mg/d respectively
Study: 24800582
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/d and Furosemide 40 mg/d, adjusted every seven days to a maximum of 400 mg/d and 160 mg/d respectively
Study: 18568687
Drug: Aggressive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive antihypertensive combination treatment
Study: 8541683
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with recombinant tissue‐type plasminogen activator for up to 4 hours followed by angioplasty (n = 11)
Study: 8541683
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (n = 4 with limb-threatening ischemia)
Study: 28256915
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dehydroepiandrosterone (DHEA)
Study: 26048317
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tirofiban at 0.075μg/kg/min for 24h
Study: 9640081
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin (CT) at a dose of 100 i.v./days s.c. for three days in patients with chronic moderate bronchial asthma
Study: 8330463
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol (2 mg on day 1, followed by 1, 2, and 4 mg every 6 hours on days 2-6, 7-11, and 12-16)
Study: 29945954
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) - single infusion of 0.8 g/kg
Study: 26894413
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus letrozole (letrozole 2.5 mg daily + palbociclib 125 mg once daily for 3 weeks followed by 1 week off)
Study: 26894413
Drug: Letrozole alone
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole alone (2.5 mg daily)
Study: 25886227
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with 8 mg dexamethasone (30 ml of 0.5% ropivacaine with 2 ml dexamethasone)
Study: 25886227
Drug: Ropivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine alone (30 ml of 0.5% ropivacaine with 2 ml distilled water)
Study: 25886227
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with 8 mg dexamethasone
Study: 23234472
Drug: Imaging-clinical examination
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging-clinical examination group (treatment based on imaging and clinical examination)
Study: 15810908
Drug: BDDrFVIII (ReFacto)
Normalized name: BDDrFVIII
DrugBank: Moroctocog alfa (DB13999)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: BDDrFVIII (ReFacto) reconstituted with 5 mL of sterile water
Study: 15810908
Drug: BDDrFVIII (ReFacto)
Normalized name: BDDrFVIII
DrugBank: Moroctocog alfa (DB13999)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: BDDrFVIII (ReFacto) reconstituted with 4 mL sodium chloride 0.9% USP
Study: 15810908
Drug: Hemofil M
Normalized name: HEMOFIL M KIT
DrugBank: Antihemophilic factor human (DB13192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemofil M (plasma-derived, full-length FVIII preparation)
Study: 6379574
Drug: Scrub A
Normalized name: Cleanser Topical application Pad [OCUSOFT LID SCRUB ALLERGY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrub A (chlorhexidine digluconate 40 mg/ml)
Study: 6379574
Drug: Scrub B
Normalized name: BD Posif Surescrub BD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrub B (benzalkonium chloride 5 mg/ml)
Study: 27438687
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus continuation venlafaxine monotherapy
Study: 20361031
Drug: Albendazole therapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole therapy
Study: 3336984
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol followed by oral metoprolol
Study: 31688452
Drug: Valbenazine 40
Normalized name: valbenazine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 40 mg/d
Study: 31688452
Drug: Valbenazine 80
Normalized name: valbenazine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 80 mg/d
Study: 30695293
Drug: Valbenazine 40
Normalized name: valbenazine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 40 and/or 80 mg/d
Study: 24381187
Drug: Aerosolized albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized albuterol (intervention group)
Study: 20446889
Drug: Osteoporosis medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoporosis medications
Study: 12439707
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg m(‐2) every 3 weeks)
Study: 12439707
Drug: 5-fluorouracil (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (750 mg m(‐2) per day continuous infusion D1-5) plus vinorelbine (25 mg m(‐2) D1 and D5 of each 3-week cycle
Study: 2022561
Drug: recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant DNA human GH (rhGH) 0.07 U/kg body wt daily for 6 months
Study: 7225166
Drug: Fenofibrate 400
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 400 mg/day
Study: 7225166
Drug: Clofibate 2
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofibate 2 g/day
Study: 25884724
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (two different daily doses)
Study: 23630052
Drug: Beta-alanine (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (65 mg · kg ‐ 1BM)
Study: 19515873
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg), vitamin B(12) (400 microg), vitamin B(6) (10 mg) daily
Study: 15673860
Drug: dolasetron 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dolasetron 12.5 mg IV
Study: 10555719
Drug: Monthly retrospective
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly retrospective written feedback mailed to residents detailing their missed immunization opportunities and appointment failure rates over a 12‐month period.
Study: 8677278
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (ultrasound alone)
Study: 6315514
Drug: High fibre
Normalized name: Adult high protein high fibre formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fibre diet (51.4 g dietary fibre/24 h)
Study: 6315514
Drug: Standard dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dietary advice (12.4 g dietary fibre/24 h)
Study: 30625398
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) with adjunct antimicrobial photodynamic therapy (aPDT)
Study: 28642208
Drug: Imagery-enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery-enhanced cognitive behavioral group therapy (IE-CBGT)
Study: 28642208
Drug: Verbally-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbally-based cognitive behavioral group therapy (VB-CBGT)
Study: 25680595
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) with oxaliplatin 130 mg/m² on day 1 and S1 at 40 mg/m² twice daily on days 1‐14, followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m² on days 1 and 21 and S1 30 mg/m² twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A)
Study: 25680595
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) followed by esophagectomy without ICT (arm B)
Study: 25680595
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) with oxaliplatin and S1 (arm A)
Study: 25680595
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) without ICT (arm B)
Study: 16013776
Drug: FDC formulations
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC formulations containing rifampicin, isoniazid, and ethambutol hydrochloride